Alx Oncology Holdings Q3 2026 Results: Net Loss of $21.8M, Loss Narrows
ALX Oncology reported a net loss of $57.7 million for the nine months ended September 30, 2026, an improvement from the $78.8 million loss in the prior year period. The company significantly strengthened its balance sheet through equity offerings, increasing total stockholders' equity to $125.9 million from $26.0 million at the end of 2025.
- Key figure
- Net loss $21.8M